Source: Eur Respir J, 54 (1) 1801896; 10.1183/13993003.01896-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Emily Henkle, Jeffrey R. Curtis, Lang Chen, Benjamin Chan, Timothy R. Aksamit, Charles L. Daley, David E. Griffith, Kevin L. Winthrop. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J, 54 (1) 1801896; 10.1183/13993003.01896-2018

Member's Comments

No comment yet.

Related content which might interest you: Comparative studies of inhaled corticosteroids in asthma Source: Eur Respir J 2001; 17: 579-580 Year: 2001 Exacerbations and inhaled corticosteroids in bronchiectasis patients Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis Year: 2019 Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis Source: ERJ Open Res, 8 (1) 00786-2020; 10.1183/23120541.00786-2020 Year: 2022 Rationale for use of inhaled steroids in children with bronchiectasis Source: International Congress 2019 – Insights into paediatric bronchology Year: 2019 Risks of pneumonia in asthmatic patients taking inhaled corticosteroids Source: Annual Congress 2010 - Management of airway disease Year: 2010 An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Efficacy of systemic corticosteroids in refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β2 agonist inhalation Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010 Effects of inhaled corticosteroids on cough in asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 347s Year: 2004 Anti-inflammatory therapies in bronchiectasis Source: Eur Respir Mon 2011; 52: 223-238 Year: 2011 Co-dispensing of inhaled corticosteroids and antibiotics Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care Year: 2012 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Low-dose inhaled and nasal corticosteroid use and the risk of cataracts Source: Eur Respir J 2006; 27: 1168-1174 Year: 2006 Comparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate-severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 Effects of montelukast on tapering inhaled corticosteroids in patients with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 260s Year: 2001 Effects of montelukast on tapering inhaled corticosteroids in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 407s Year: 2002 Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016 Year: 2017 Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Inhaled corticosteroids and hospitalisation due to exacerbation of COPD Source: Eur Respir J 2003; 22: 286-289 Year: 2003